High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction
ACS Chemical Biology · 2026-10-13
DOI: 10.1021/acschembio.6c00599 ↗At a glance
Journal article in ACS Chemical Biology, published online on 2026-10-13. Written by Caiqin Wang and 11 co-authors. Institution: Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts01003, USA. 52 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIA NIH HHS, Alzheimer's Drug Discovery Foundation, National Institute on Aging.
Abstract (original language)
The cellular uptake and propagation of tau are central features of tauopathies, including Alzheimer’s disease, and are mediated by the endocytic receptor low-density lipoprotein receptor-related protein 1 (LRP1). While prior studies have implicated LRP1 in tau binding and internalization, the biochemical features of this interaction and its suitability for therapeutic targeting remain incompletely defined. Here, we establish a quantitative and scalable framework to interrogate the tau-LRP1 interaction and identify small-molecule modulators. We engineered and purified the LRP1 ligand-binding domain 4 (BD4), a key region mediating tau interaction, and developed multiple orthogonal assays, including fluorescence polarization, split luciferase complementation, and time-resolved FRET, to measure LRP1-BD4 interactions with tau and a known peptide ligand. Across assay formats, we observe consistent binding affinities in the nanomolar range and demonstrate competitive displacement by tau, receptor-associated protein (RAP), and a peptide ligand, supporting overlapping binding interfaces. Leveraging these platforms, we performed small-molecule high-throughput screening and identified a set of candidate inhibitors of the LRP1-BD4-tau interaction. Selected compounds reduced tau uptake in a cellular assay, phenocopying competitive inhibition by tau and a peptide ligand. Together, these studies define the LRP1-BD4-tau interaction as a biochemically tractable and druggable interface and establish an integrated discovery pipeline linking mechanistic characterization to functional cellular outcomes. This work provides a foundation for the development of therapeutic strategies targeting LRP1-mediated tau uptake.
Authors and institutions
- Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts01003, USA.
- Molecular and Cellular Biology Graduate Program, University of Massachusetts, Amherst, Massachusetts01003, USA.
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys, La Jolla, California92037, USA.
- Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California93106-9010, USA.
ORCID profiles: Jennifer N Rauch
Funding
- NIA NIH HHS
- Alzheimer's Drug Discovery Foundation
- National Institute on Aging
- University of Massachusetts
Cite
APA
Wang, C., Ma, C. T., Crotty, C., Zeng, F. Y., Bobkov, A., Covel, J. A., Rivera, E. K., Sergienko, E., Kosik, K. S., Olson, S. H., Jackson, M. R., & Rauch, J. N. (2026). High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00599
Vancouver
Wang C, Ma CT, Crotty C, Zeng FY, Bobkov A, Covel JA, et al. High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00599
BibTeX
@article{Wang2026,
author = {Wang, Caiqin and Ma, Chen-Ting and Crotty, Camryn and Zeng, Fu-Yue and Bobkov, Andrey and Covel, Jonathan A and Rivera, Erica Keane and Sergienko, Eduard and Kosik, Kenneth S and Olson, Steven H and Jackson, Michael R and Rauch, Jennifer N},
title = {High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction},
journal = {ACS Chemical Biology},
year = {2026},
doi = {10.1021/acschembio.6c00599}
}
EUVIMED